Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer

NCT02082210 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02082210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02082210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
March 7, 2014
Completion date
January 24, 2018
Enrollment
97 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular cancer, non-small cell lung cancer, renal cell carcinoma